SCHEMBL6525635

SCHEMBL6525635

O=c1[nH]c2ncccc2c2cc(NCCc3ccccn3)ccc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.56
PARP1 P09874 1/20 0.56
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CYP1A2 P05177 1/20 0.45
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44
AURKB Q96GD4 1/20 0.41
GBA1 P04062 1/20 0.41
DAO P14920 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
PIM1 P11309 1/20 0.40
TSHR P16473 1/20 0.40
LMNA P02545 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
PARP14 Q460N5 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6533053 0.80 AURKA (0.54) AURKAPARP1CYP1A2PIM1ALDH1A1
SCHEMBL3454371 0.79 AURKA (0.60) AURKAPARP1ADORA2AAURKBPIM1
SCHEMBL6521479 0.79 CDK2 (0.50) AURKAPARP1NPC1RAB9ACYP1A2
SCHEMBL3454715 0.78 AURKA (0.55) AURKAPARP1CYP1A2AURKBPIM1
SCHEMBL6523008 0.78 PARP1 (0.51) AURKAPARP1HRH3
SCHEMBL6517375 0.78 AURKA (0.51) AURKAPARP1NPC1RAB9AAURKB
SCHEMBL6521930 0.76 PARP1 (0.52) AURKAPARP1LMNAALDH1A1
SCHEMBL6517435 0.76 AURKA (0.67) AURKAPARP1ADORA2AADORA1AURKB
SCHEMBL6522266 0.76 AURKA (0.55) AURKAPARP1RAB9AALDH1A1PARP14
SCHEMBL6521905 0.75 AURKA (0.55) AURKAPARP1PIM1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885NPC1 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.